Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 11/20 | 0.48 |
| ▸ | STS | P08842 | 3/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2401854 | 0.79 | CYP19A1 (0.71) | CYP19A1STSMAPT | |
| SCHEMBL305817 | 0.79 | CYP19A1 (0.75) | CYP19A1STS | |
| SCHEMBL306767 | 0.77 | CYP19A1 (0.76) | CYP19A1STSPDE4B | |
| SCHEMBL16044983 | 0.77 | CYP19A1 (0.49) | CYP19A1STSPDE4B | |
| SCHEMBL24278182 | 0.75 | LMNA (0.42) | CYP19A1MAPK1TDP1MAPTSMN1; SMN2 | |
| SCHEMBL28206691 | 0.75 | CYP19A1 (0.53) | CYP19A1MAPK1TDP1MAPTTSHR | |
| SCHEMBL16044173 | 0.73 | CYP19A1 (0.58) | CYP19A1STSPDE4B | |
| SCHEMBL25343573 | 0.73 | ALDH1A1 (0.60) | CYP19A1MAPK1TDP1TSHR | |
| SCHEMBL16046728 | 0.72 | PDE4B (0.49) | CYP19A1PDE4BTSHRPDE4D | |
| SCHEMBL305954 | 0.70 | CYP19A1 (0.61) | CYP19A1STSMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093279-B2 | Compound | STERIX LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-20100173963-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173963-A1 | COMPOUND | CBR3, CBR1, OXSR1 | CYP19A1 605/4885STS 1844/4885PDE4B 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.